Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O14802
UPID:
RPC1_HUMAN
Alternative names:
DNA-directed RNA polymerase III largest subunit; DNA-directed RNA polymerase III subunit A; RNA polymerase III 155 kDa subunit; RNA polymerase III subunit C160
Alternative UPACC:
O14802; Q8IW34; Q8TCW5
Background:
DNA-directed RNA polymerase III subunit RPC1, also known as the largest subunit of RNA polymerase III, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates as substrates. It is crucial for synthesizing small RNAs, including 5S rRNA and tRNAs, and forms the polymerase active center with the second largest subunit. This protein is also involved in the innate immune response, sensing and limiting infection by intracellular bacteria and DNA viruses by sensing non-self dsDNA.
Therapeutic significance:
The involvement of DNA-directed RNA polymerase III subunit RPC1 in Leukodystrophy, hypomyelinating, 7, and Wiedemann-Rautenstrauch syndrome, underscores its potential as a target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies for these neurodegenerative and progeroid disorders.